160 related articles for article (PubMed ID: 22674382)
1. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.
Yang H; Liang H; Yan JS; Tao R; Hao SG; Ma LY
Int J Hematol; 2012 Jul; 96(1):65-73. PubMed ID: 22674382
[TBL] [Abstract][Full Text] [Related]
2. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
3. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3.
Yang MY; Chang JG; Lin PM; Tang KP; Chen YH; Lin HY; Liu TC; Hsiao HH; Liu YC; Lin SF
Cancer Sci; 2006 Dec; 97(12):1298-307. PubMed ID: 16999817
[TBL] [Abstract][Full Text] [Related]
5. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
7. JunB gene expression is inactivated by methylation in chronic myeloid leukemia.
Yang MY; Liu TC; Chang JG; Lin PM; Lin SF
Blood; 2003 Apr; 101(8):3205-11. PubMed ID: 12506033
[TBL] [Abstract][Full Text] [Related]
8. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Vatanmakanian M; Tavallaie M; Ghadami S
Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
[TBL] [Abstract][Full Text] [Related]
9. Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells.
Imoto A; Okada M; Okazaki T; Kitasato H; Harigae H; Takahashi S
J Biol Chem; 2010 Apr; 285(14):10300-9. PubMed ID: 20139074
[TBL] [Abstract][Full Text] [Related]
10. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
12. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Jelinek J; Gharibyan V; Estecio MR; Kondo K; He R; Chung W; Lu Y; Zhang N; Liang S; Kantarjian HM; Cortes JE; Issa JP
PLoS One; 2011; 6(7):e22110. PubMed ID: 21760961
[TBL] [Abstract][Full Text] [Related]
14. DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
Li Y; Liu X; Guo X; Liu X; Luo J
Leuk Res; 2017 Jul; 58():9-13. PubMed ID: 28376405
[TBL] [Abstract][Full Text] [Related]
15. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
16. GPX3 promoter is methylated in chronic myeloid leukemia.
Yao DM; Zhou JD; Zhang YY; Yang L; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Int J Clin Exp Pathol; 2015; 8(6):6450-7. PubMed ID: 26261521
[TBL] [Abstract][Full Text] [Related]
17. Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells.
Gutiérrez P; Delgado MD; Richard C; Moreau-Gachelin F; León J
Biochem Biophys Res Commun; 1997 Nov; 240(3):862-8. PubMed ID: 9398659
[TBL] [Abstract][Full Text] [Related]
18. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
Li Z; Luo J
Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
Ortmann CA; Burchert A; Hölzle K; Nitsche A; Wittig B; Neubauer A; Schmidt M
Nucleic Acids Res; 2005; 33(21):6895-905. PubMed ID: 16396836
[TBL] [Abstract][Full Text] [Related]
20. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]